Contakt World Becomes Data Partner for Health Equity Tracker Project to Improve the Collection of De-Identified Racial & Ethnic Minority Data Using Smart Health RM, Engagency, and Future Services

Enables Contakt World mission to improve health equity and reduce disparities in the fight against Covid-19 and all diseases via award-winning SaaS platform

Covid-19 has proven to be the "great revealer" of disparities in healthcare
Contakt World (CSE: HELP) and Satcher Health Leadership Institute, Morehouse School of Medicine executed a strategic collaboration in October 2020

Health Equity Tracker, supported by Google.org, Gilead Sciences (Nasdaq: GILD), Annie E. Casey Foundation, and CDC Foundation, is now operational

Contakt World's SaaS Platform, Smart Health RM, will help drive de-identified data to Health Equity Tracker to improve health equity and reduce disparities of care

Contakt World Technologies Corp. (CSE: HELP) (OTC: TLOOF) (FSE: B2I0) (the "Company" or "Contakt World") today announced its agreement in principle with Satcher Health Leadership Institute, Morehouse School of Medicine ("SHLI") to help collect de-identified demographic data for the Health Equity Tracker Project through Smart Health RM and other products and services provided by Contakt World like Engagency. This updates the previously announced collaboration between Contakt World and SHLI now that Health Equity Tracker is operational.

Justin Beck, Chief Visionary Officer ("CVO") for Contakt World, said, "National health equity leader Daniel E. Dawes teaches us that you can't fix problems you don't understand via data. The systemic omission or destruction of racial and ethnic data in public health and healthcare systems mean that disparities often aren't addressed politically - sometimes by design."

He added, "We learned about this on Episode 2 of Contakt World: Truth in Health on iHeartRadio entitled 'COVID The Great Revealer' in my exclusive interview with Daniel E. Dawes, and through Daniel's book published by Johns Hopkins University Press: The Political Determinants of Health. We learned about the oppression of data again, particularly among American Indian and Alaska Natives, speaking with Abigail Echo-Hawk, Chief Research Officer at Seattle Indian Health Board and Director of the Urban Indian Health Institute, on Episode 8 of Contakt World: Truth in Health entitled 'General Disparities? Or Data Genocide?'"

A long-term initiative of the leading institution Satcher Health Leadership Institute at Morehouse School of Medicine ("SHLI"), Health Equity Tracker ("HET") was designed to improve collection and transparency for key demographic data so we can address disparities in healthcare and ultimately improve outcomes for the most vulnerable among us who have suffered from 150+ years systemic inequities. HETP was designed through SHLI's Health Equity Task Force, which involved thought leadership from leaders all over the country in health equity, public health, healthcare, pandemic response, epidemiology, members of Congress in the United States, and Contakt World's co-founder and board member Robin Coleman, a publisher for Johns Hopkins University Press. Funding from Google.org, Gilead Sciences, Annie E. Casey Foundation, and CDC Foundation enabled the project in its formative stages.

"Since the launch of our Health Equity Task Force, Contakt World has been a critical partner in propelling actionable solutions and thought leadership into action," said Daniel E. Dawes. "Now that the HET is operational, Smart Health RM can help collect de-identified data from public health agencies and healthcare where gaps exist as a data partner for Health Equity Tracker. Engagency can also help to identify underserved populations and drive them to their local health department or provider, leveraging Contakt World's agency partnership with Unified Partnerships via iHeartMedia."

"Health agencies, organizations like National Association of County and City Health Officials ("NACCHO"), and public health professionals prioritize health equity in all they do. We hope our data partnership with HET continues to distinguish Contakt World, much like our innovation around communications and community engagement does," added CVO Beck.

"Since the launch of our Health Equity Task Force, Contakt World has been a critical partner in propelling actionable solutions and thought leadership into action," said Daniel E. Dawes. "Now that the HET is operational, Smart Health RM can help collect de-identified data from public health agencies and healthcare where gaps exist as a data partner for Health Equity Tracker. Engagency can also help to identify underserved populations and drive them to their local health department or provider, leveraging Contakt World's agency partnership with Unified Partnerships via iHeartMedia."

Contakt World Contact
Zayn Kalyan
Interim CEO and Director
Direct: 778-938-3367

For more information, please visit the Company's website at www.contakt.world.

Contakt World Investor Contact
Lucas A. Zimmerman
Senior Vice President - MZ North America
Direct: 949-259-4987
contakt@mzgroup.us
www.mzgroup.us

Forward-Looking Statements

Certain information set forth in this press release contains statements that reflect "forward-looking information", as such term is defined under Canadian securities laws ("forward-looking statements"). These forward-looking statements are often identified by words such as "intends", "anticipates", "expects", "believes", "plans", "likely" or similar words. Specifically, this news release includes forward-looking statements regarding: the Company's partnership with SHLI; the HET program's intention and implementation; the planned integration of Smart Health RM and Engagency into the HET program; Contakt's intention to launch vaccine hesitancy ads for SHLI; the Company's long-term view and future business plans. The forward-looking statements reflect the Contakt World's management's expectations, estimates, or projections concerning future results or events, based on the opinions, assumptions and estimates considered reasonable by management at the date the statements are made. Although Contakt World believes that the expectations reflected in the forward-looking statements are reasonable, forward-looking statements involve risks and uncertainties and undue reliance should not be placed on forward-looking statements, as unknown or unpredictable factors could cause actual results to be materially different from those reflected in the forward-looking statements. The forward-looking statements may also be affected by risks and uncertainties in the business of Contakt World, including those described in the Company's public filings available on www.SEDAR.com. The Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change, except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

The Canadian Securities Exchange (CSE) has not reviewed, approved or disapproved the content of this news release.

Corporate Logo

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/92368

News Provided by Newsfile via QuoteMedia

Contakt World CSE:HELP Emerging Tech Investing

Syntheia Rings the Opening Bell on the Canadian Securities Exchange

Syntheia Corp. ("Syntheia" or the "Company") (Syntheia.ai), CSE SYAI, a Canadian leader in conversational AI, is pleased to announce that the Company's leadership team rang the bell to open the market in collaboration with the Canadian Securities Exchange to celebrate its successful listing under the symbol "SYAI".

" We look forward to great success through our partnership with the CSE as we commercially launch our conversational AI to the market. On behalf of the Company, I would like to thank everyone who has made this milestone happen, " commented Tony Di Benedetto, Chief Executive Officer at Syntheia.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Syntheia Set to Enhance Customer Communication with Its AI-Powered Virtual Assistant

Syntheia Corp. ("Syntheia" or the "Company") (Syntheia.ai), CSE SYAI, a Canadian leader in conversational AI, announces that its innovative SaaS platform, designed to transform how businesses manage inbound telephone calls is set to launch in January of 2025. Leveraging advanced Natural Language Processing (NLP), Syntheia's virtual assistants enhance communication and efficiency targeting small and medium businesses in this large global marketplace.

" Our mission is to eliminate as many inefficiencies as we can with managing inbound calls that small to medium-sized businesses face utilizing the power of AI" said Tony Di Benedetto, CEO of Syntheia. "With AI-driven virtual assistants, we provide these businesses with tools to improve customer satisfaction while reducing operational costs. We are gearing up now for commercial launch in January of 2025, less than 8 weeks away."

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Sona Nanotech to Showcase Its THT Cancer Therapy at NCL 20th Anniversary Symposium and Provides Corporate Update

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is pleased to announce that its Chief Scientific Officer, Dr. Len Pagliaro, has been invited to showcase Sona's developing Targeted Hyperthermia Therapy ("THT") cancer treatment today at the Nanotechnology Characterization Laboratory ("NCL"). Sona will be one of six commercial and academic collaborators to present its research at the NCL's 20th anniversary "Advancing Medical Applications of Cancer Nanotechnology" symposium. Sona's subsidiary was previously selected for the NCL Assay Cascade Program, the premier program in the World for bringing nanomaterials through critical preclinical stages and facilitating regulatory review, in which Sona's materials were assessed for biocompatibility. The NCL was established by the National Cancer Institute ("NCI") to accelerate the progress of nanomedicine by providing preclinical characterization and safety testing of nanoparticles. The NCL is a collaborative effort between NCI, the U.S. Food and Drug Administration ("FDA"), and the National Institute of Standards and Technology.